ImmunOs Therapeutics AG announced that it has received CHF 74,000,000 in a round of funding co-led by new investors GIMV NV, Lightspeed Ventures, LLC and Samsara BioCapital LLC on June 7, 2022. The transaction included participation from new investors PEAK6 Investments, L.P., GL Capital Group, Fiscus Financial Llc, Mission BioCapital, LP and returning investors Schroder Capital, Pfizer Venture Investments LLC and BioMedPartners AG. As part of the transaction, Shelley Chu of Lightspeed Ventures, LLC, Marcos Milla of Samsara BioCapital LLC and Andreas Jurgeit of GIMV NV, will join the board of directors of the company.